Novo Nordisk ups oral GLP‑1 capacity

Novo Nordisk is spending €432 million on one factory in Athlone, Ireland because the next bottleneck in weight-loss drugs is not demand anymore. It is the ability to make enough pills and pens, on time, in the right markets. (pharmtech.com) The company said on March 2, 2026 that Athlone will be expanded to make more oral glucagon-like peptide-1 drugs, with phased completion running through 2027 and 2028. Novo Nordisk also said the site will serve as a primary manufacturing hub for markets outside the United States. (novonordisk.com, pharmtech.com) That “oral” part matters because most people know semaglutide through injections like Wegovy, which the European Medicines Agency lists as pre-filled pens in doses from 0.25 milligrams to 2.4 milligrams. Pills are a different manufacturing job from injection pens, with different tableting equipment, packaging lines, and quality controls. (ema.europa.eu, pharmtech.com) Athlone is not a greenfield build on empty land. Novo Nordisk is retrofitting an existing 45-acre site that already has about 260 employees, which is usually faster than starting from scratch when a company is racing to add capacity. (pharmtech.com) This is also a geography story. By making Athlone a main hub outside the United States, Novo Nordisk gets another large production base closer to European and other international markets instead of pushing every shipment through one narrow pipe. (pharmtech.com) The second piece of news is smaller on paper but useful in practice. The European Medicines Agency updated Wegovy’s product information on March 30, 2026, after a January 15, 2026 variation procedure, which means the shipping and handling rules were formally loosened through the regulator, not just through company guidance. (ema.europa.eu, ema.europa.eu) For a drug that normally lives inside a refrigerated cold chain, even a short allowance at higher temperatures can remove friction. A truck delay, customs hold, or warehouse transfer is less likely to turn into wasted inventory if the package has a little more room to breathe. (ema.europa.eu, stocktwits.com) Put those two moves together and you get the real picture: Novo Nordisk is working on both ends of the supply problem at once. Athlone adds more output over the next two years, and the updated Wegovy handling rules make each box a little easier to move through Europe right now. (pharmtech.com, ema.europa.eu, stocktwits.com) That is why a factory retrofit in central Ireland and a dry regulatory update in Amsterdam belong in the same story. One increases how much semaglutide Novo Nordisk can make, and the other reduces how easily that supply can get stuck between the factory and the patient. (pharmtech.com, ema.europa.eu)